Biology

#Biology #Drug discovery #Protein chemistry / Proteomics #Therapeutics

Why the emergence of targeted protein degradation is so exciting 

Listen to this article on the DDW Podcast: Last year a new translational research centre was established to bolster the University of Dundee’s drug discovery position. The Centre for Targeted Protein Degradation (CeTPD) would allow Professor Alessio Ciulli and colleagues to expand their pioneering work in an area that has… Read More

#hidden

#Biology #Biosciences #Life sciences #Proteomics

Alamar and Abcam to drive understanding of human proteomes 

Alamar Biosciences, a proteomics platform, and Abcam, innovators in life sciences research tools, have partnered to further their understanding of the human proteome.  Proteomics  The field of proteomic analysis is in the spotlight. Its advance not only enhances the understanding of fundamental biology, but also… Read More

#News

#Biology #Drug development #Therapeutics

Closing drug development gaps with new clinical prediction AI 

Quris, an artificial intelligence (AI) company in the pharmaceutical industry, has launched a clinical prediction AI platform to predict which drug candidates will safely work in humans. This will improve efficacy and cut drug development costs.   What do they do?  Quris uses AI-powered miniaturised “patients-on-a-chip” to avoid… Read More

#News #Videos

#Autoimmune disease #Biology #Drug development #Drug discovery #Research study #Therapeutics

Human-on-a-Chip approach validated to model rare autoimmune disease

A new peer-reviewed article demonstrated that Hesperos’ Human-on-a-Chip (HoaC) cell-based neuromuscular junction (NMJ) platform system can mimic the disease phenotypes of myasthenia gravis (MG). The manuscript, titled “A Functional Human-on-a-Chip Autoimmune Disease Model of Myasthenia Gravis for Development of Therapeutics,” was published in Frontiers in Cell and Developmental Biology. Read More

#News

#Biology #Collaboration #Covid-19 #Research

CN Bio and iiCON announce Covid-19 research collaboration

CN Bio has entered a research collaboration with the Infection Innovation Consortium (iiCON) to validate the next generation of Covid-19 research tools.  iiCON’s £174 million programme brings together industry, academia, and clinicians to accelerate the discovery, development and deployment of new treatments and products. Led by the Liverpool School of… Read More

#Covid-19 #News #Trending News

#Biology #Data #Drug discovery #Metabolomics #Precision medicine #Research

New metabolomics solution enables understanding of the microbiome 

Metabolon’s first offering from its SmartPanel portfolio aims to provide drug discovery and precision medicine researchers with a novel, dynamic process to explore biologically relevant views of metabolomic data in the context of specific metabolic pathways, biological themes, and disease associations.  “The metabolome offers a window into human… Read More

#Editor's Choice #News #Trending News

#Biology #Covid-19 #Research

SARS-CoV-2 virus does not infect blood vessels, study shows 

University of Queensland (UQ) researchers have found that the SARS-CoV-2 virus does not infect blood vessels, despite the high risk of blood clots in Covid-19 patients. They found that the cardiovascular complications of Covid-19 are triggered by inflammation caused by infected airway cells.  Dr Emma Gordon and… Read More

#News #Trending News

#Biology #DNA #Funding #Life sciences

DNA Script raises $165M to accelerate enzymatic DNA printing platform  

DNA Script has raised $165 million in a Series C financing led by Coatue Management and Catalio Capital Management, whose representatives have joined as board observers. The new funds will be used to accelerate expansion and commercialisation of the company’s SYNTAX Platform and broaden the portfolio of products powered by EDS.  DNA Script… Read More

#News

#Biology #Drug development #Infectious diseases #MPS technology #Novel therapeutics #Organ-on-a-chip #Toxicology

Hype or hope – microphysiological systems?

Listen to this article on the DDW Podcast: Dr Tomasz Kostrzewski, Director of Biology at CN Bio Innovations, examines MPS in drug discovery as part of a preclinical toolbox.  Drug development remains slow and costly for the pharmaceutical industry, driven by the financial impact of late-stage failures of drug candidates1. Although… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Biology #Cancer research #Immuno-oncology #Systems biology #Therapeutics #Webinar

Targeted protein degradation: learn from an expert 

Challenges and Opportunities in Protein Degradation, is free webinar hosted by DDW and supported by Cell Signaling Technology (CST). It took place on 21 October, 2021 and is now available to watch on demand for free here.   Dr. Nathanael Gray, Professor of… Read More

#News

#Antibodies #Biology #Genes

Sino Biological listed on the Shenzhen Stock Exchange 

Sino Biological has announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext. A total of 17 million shares were issued for a total of ¥4.98 billion (US$770 million) raised during this initial public offering.   Sino Biological says the listing is an important milestone in its strategic plan for growth. It signifies a new starting… Read More

#Business & Investment #News

#Biologics #Biology #Data #Genetics / genomics #RNA #Therapeutics

Starting line: focus on Canadian start-ups

DDW Editor Lu Rahman selects three Canadian start-ups worth watching: AbCellera Biologics, BlueRock Therapeutics and Deep Genomics. AbCellera Biologics AbCellera Biologics was founded in 2012 as a spin out from the University of British Colombia. The company searches, decodes, and analyses natural immune systems to find antibodies that can be… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion #Start-up Zone

#Biology #Cancer #Cancer research #Drug discovery #Therapeutics

Researchers develop novel therapy that could be effective in many cancers

Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery. The therapy is an engineered molecule called MS21 that causes the degradation of AKT, an enzyme that is overly… Read More

#Cancer Research #News #Trending News

#AI #Biology #R&D #Therapeutics #Tumour biology

Combining AI-driven drug capabilities with CDK targets for oncology

Exscientia and GT Apeiron Therapeutics have entered an R&D collaboration. Exscientia’s AI expertise will  be used to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. This collaboration follows the design of… Read More

#News

#Biology #Biotechnology #Drug development #Drug discovery #Life sciences #SLAS 2021

Poster award deadlines approaching for SLAS 2021

The deadlines for the Tony B. Academic Award and the Student Poster Award for SLAS Europe 2021 is June 14, a week prior to the conference, which takes place June 23-25 digitally. SLAS’ call for poster abstracts provide opportunities to receive recognition, experience and praise for original research by a… Read More

#News